Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zogenix revenue
Zogenix's revenue is $81.7 million.
What is Zogenix's revenue?
- Zogenix's revenue growth from 2010 to 2021 is 248.48%.
- Zogenix has 90 employees, and the revenue per employee ratio is $907,666.
- Zogenix's peak quarterly revenue was $26.6M in 2021(q4).
- Zogenix peak revenue was $81.7M in 2021.
- Zogenix annual revenue for 2020 was 13.6M, 273.99% growth from 2019.
- Zogenix annual revenue for 2021 was 81.7M, 498.77% growth from 2020.
On this page
Zippi applies for you, and finds you a job.
Zogenix historical revenue
Zogenix's peak revenue was $81.7M in 2021. The peak quarterly revenue was $26.6M in 2021(q4).
Zogenix's revenue increased from $23.4m in 2010 to $81.7M currently. That's a 248.48% change in annual revenue.
Zogenix annual revenue
Zogenix annual revenue over time
| Fiscal year / year | Zogenix revenue |
|---|---|
| 2010 | $23.4M |
| 2011 | $37.6M |
| 2012 | $44.3M |
| 2013 | $33.0M |
| 2014 | $28.9M |
| 2015 | $27.2M |
| 2016 | $28.9M |
| 2017 | $9.8M |
| 2019 | $3.6M |
| 2020 | $13.6M |
| 2021 | $81.7M |
Rate Zogenix's financial transparency
Zogenix annual growth
Zogenix saw the greatest revenue growth in 2021, when revenue increased by 498.77%.
Zogenix had the lowest revenue growth in 2017, when revenue changed by -65.96%.
Zogenix annual growth rate over time
| Year | Zogenix growth |
|---|---|
| 2011 | 60%↑ |
| 2012 | 18%↑ |
| 2013 | -26%↓ |
| 2014 | -12%↓ |
| 2015 | -6%↓ |
| 2016 | 6%↑ |
| 2017 | -66%↓ |
| 2019 | -63%↓ |
| 2020 | 274%↑ |
| 2021 | 499%↑ |
Zogenix quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Zogenix quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | $10.2M | $10.4M | $7.9M |
| 2012 | $18.3M | $8.0M | $8.5M | $9.5M |
| 2013 | $7.0M | $8.9M | $7.2M | $9.9M |
| 2014 | $7.4M | $6.7M | $4.9M | $9.9M |
| 2015 | $4.6M | $7.4M | $9.1M | $6.1M |
| 2016 | $9.2M | $2.1M | $6.6M | $11.0M |
| 2017 | $2.7M | $7.1M | - | - |
| 2019 | - | $1.1M | $630,000 | $1.9M |
| 2020 | $1.2M | $1.0M | $2.9M | $8.5M |
| 2021 | $13.7M | $18.8M | $22.6M | $26.6M |
Zogenix jobs nearby
Do you work at Zogenix?
Did Zogenix meet its revenue projections?
Zogenix financial information
| CEO | Stephen J. Farr |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 90 |
| Date Founded | 2006 |
| Headquarters | Emeryville, California |
| Number of Locations | 1 |
| Revenue | $81.7M |
| Net Income | -$227,413,000 |
| Gross Proft | $76.9M (2021) |
| EBITDA | ($204.8M) (2021) |
| PE Ratio | -6.47 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.5B |
| Total Assets | $468,489,000 |
| Ticker | ZGNX |
Zogenix jobs you might like
Zogenix financing
Zogenix received early financing of $60.0M on 2006-08-28.
| Series | Round size | Date |
|---|---|---|
| Series A | $60M | 08/2006 |
| Series B | $18M | 01/2008 |
| Debt Financing | $3.1M | 05/2009 |
| Series B | $36.0M | 10/2009 |
| Series B | $35M | 12/2009 |
| Series Unknown | $15M | 07/2010 |
| Debt Financing | $35M | 07/2010 |
| Post Ipo Equity | $60M | 09/2011 |
| Post Ipo Equity | $98.3M | 07/2015 |
| Post Ipo Equity | $69M | 11/2016 |
| Post Ipo Equity | $288.9M | 10/2017 |
| Post Ipo Equity | $312M | 08/2018 |
| Post Ipo Equity | $230.3M | 03/2020 |
| Post Ipo Equity | $230M | 09/2020 |
Zogenix investors
| Investors | Security type |
|---|---|
| Thomas McNerney & Partners | Series A |
| Life Science Angels Inc | Series A |
| Scale Venture Partners | Series A |
| CLARUS VENTURES LLC | Series A |
| Domain Associates | Series A |
| Abingworth | Series B |
| Scale Venture Partners | Series B |
| CLARUS VENTURES LLC | Series B |
| Domain Associates | Series B |
| Oxford Finance LLC | Series B |
| Abingworth | Series B |
| Scale Venture Partners | Series B |
| CLARUS VENTURES LLC | Series B |
| Domain Associates | Series B |
| Chicago Growth Partners | Series B |
| Oxford Finance LLC | Series Unknown |
| Thomas McNerney & Partners | Series Unknown |
| Scale Venture Partners | Series Unknown |
| Chicago Growth Partners | Series Unknown |
| CLARUS VENTURES LLC | Series Unknown |
| Domain Associates | Series Unknown |
| Oxford Finance LLC | Debt Financing |
| Silicon Valley Bank | Debt Financing |
Zogenix competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Neurelis | - | $3.0M | 300 | - |
| Aquestive Therapeutics | - | $57.6M | 100 | - |
| Tonix Pharmaceuticals | - | $12.7M | 26 | - |
| Saol Therapeutics | - | $2.2M | 66 | - |
| Seelos Therapeutics | - | $375,000 | 10 | - |
| NeuroTherapeutics Pharma Inc | - | - | 1 | - |
| Axial Therapeutics | - | $350,000 | 30 | - |
| Omeros | - | $29.9M | 265 | - |
| Endo Pharmaceuticals Inc | - | $2.6B | 385 | - |
| Allergan plc | - | $7.2B | 11,400 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Zogenix, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Zogenix. The employee data is based on information from people who have self-reported their past or current employments at Zogenix. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Zogenix. The data presented on this page does not represent the view of Zogenix and its employees or that of Zippia.
Zogenix may also be known as or be related to ZOGENIX INC, ZOGENIX INC., Zogenix, Zogenix Inc, Zogenix Inc. and Zogenix, Inc.